FMP
OncoCyte Corporation
OCX
NASDAQ
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
2.08 USD
-0.04 (-1.92%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
68.8k
45.63k
15.23k
717.85k
1.13M
169.09k
84.55k
42.27k
21.14k
10.57k
-0.78
0.04
-0.01
1.17
0.85
0.25
0.25
0.25
0.25
14.73M
18.1M
19.02M
14.06M
15.51M
-8.29M
-4.14M
-2.07M
-1.04M
-517.91k
-167.95
14.78
-11.1
22.93
11.57
-12.36
-12.36
-12.36
-12.36
-
-
-
14.06M
-
3.07M
1.54M
768.55k
384.27k
192.14k
-
-
-
22.93
-
4.59
4.59
4.59
4.59
17.1M
18.95M
1.1M
4.53M
12.56M
-9.17M
-4.58M
-2.29M
-1.15M
-573.07k
-194.92
15.48
-0.64
7.4
9.37
-13.68
-13.68
-13.68
-13.68
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-